B

Bruker

Manufactures analytical instruments for NMR diagnostics

Business Controller

Full-TimeDeadline 8/17/27
No salary listed
Mid
Bachelor's
Ettlingen, Germany
HybridOn-site work is preferred, with up to two home-office days per week by arrangement.
Finance & BankingCorporate Finance & FP&A

About the job

Requirements
  • A completed degree in business administration with a focus on accounting or controlling, or an equivalent vocational or academic background, is required.
  • Several years of finance experience in an internationally operating manufacturing company are required; experience with transactional processes and reporting in a virtually divided working model is desirable.
  • Advanced knowledge of United States Generally Accepted Accounting Principles is required.
  • Very good knowledge of SAP FI, CO, and PCA is required.
  • Very good knowledge of Microsoft Excel and PowerPoint is required.
  • Native-level German is required, along with conversationally fluent spoken and written English.
  • The role requires numerical affinity, analytical thinking, a structured working approach, the ability to prioritize and advance parallel activities, commitment, initiative, and a high degree of independent action.
  • The role requires teamwork, open communication, and a solution-oriented approach.
Responsibilities
  • Support the Optics Division with transparent, meaningful reporting and analyses of business performance, as well as business planning.
  • Prepare monthly and quarterly closings under United States Generally Accepted Accounting Principles in cooperation with accounting and present the Optics Group in the corporate reporting system.
  • Provide support for the German Commercial Code closing.
  • Collect and validate inputs and prepare financial variance and trend analyses for the balance sheet and profit and loss statement, including commentary for management.
  • Act as a business partner for research and development and platform functions by reporting and analyzing actuals against the prior year and budget.
  • Manage forecast and budget planning processes, including collecting and preparing inputs and implementing them in the planning system.
  • Perform cost allocations and apportionments during the monthly closing.
  • Report headcount and capital expenditures for the Optics Division at both local-entity and global levels.
  • Maintain, develop, and improve reporting processes.
  • Further develop and maintain the division's key performance indicators.
  • Perform controlling for the Optics Group's global inventory of demonstration devices.
Desired Qualifications
  • Experience with SAP S/4HANA, SAP BPC, and SAP SAC is desirable.
  • Experience with Microsoft Access is desirable.

About the company

Bruker makes analytical and diagnostic instruments used by researchers and industries. Its products help analyze materials and biological samples to reveal chemical structure, composition, and properties, with notable roots in nuclear magnetic resonance (NMR) technology and a broad portfolio beyond that field. The company works by designing and selling instruments such as analytical tools that collect data from samples (for example, signals from nuclei in NMR or other spectroscopic methods) and provide insights to researchers. Bruker differentiates itself through a long history of developing advanced technologies, a focus on innovation in scientific instrumentation, and a global product range serving life sciences, materials science, and environmental analysis, supported by steady investment in research and development. Its goal is to equip researchers and industries with reliable tools to push the boundaries of what is possible in science and discovery.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Billerica, Massachusetts

Founded

1960

Get referred to Bruker

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • September 28, 2026 timsUltra AIP and timsOmni launches deepen proteomics and oligonucleotide workflows.
  • August 10, 2026 MIMETAS deal expands Bruker into human-relevant drug discovery models.
  • UC Berkeley ordered over $6 million of Bruker NMR systems, delivering 2027 revenue.

What critics are saying

  • Bruker’s first-half 2026 organic revenue declined 0.8%, exposing fragile demand recovery.
  • Academic spending stayed soft in 2026, while tariffs and currency pressured results.
  • If MIMETAS and fusion remain niche, Bruker’s acquisition-heavy strategy destroys capital returns.

What makes Bruker unique

  • Bruker owns timsTOF proteomics, NMR, microscopy, and microphysiological systems under one platform.
  • Bruker’s August 31 XFlash 7200 FIRE raises SEM-EDS throughput beyond conventional detector designs.
  • Bruker’s BEST superconductors supply ITER, Wendelstein 7-X, CERN, and fusion demonstrators.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Employee Stock Purchase Plan
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Disability Insurance
  • Life Insurance
  • Dental Insurance
  • Flexible Work Hours
  • Employee Discounts

Growth & Insights and Company News

Headcount

6 month growth

10%

1 year growth

13%

2 year growth

13%
Business Wire
Oct 14th, 2026
Bruker Completes Acquisition of PhenomeX

Bruker Corporation (Nasdaq: BRKR) today announced that it has completed the acquisition of PhenomeX, a leading provider of single-cell biology research tools...

Financial Times
Sep 28th, 2026
Bruker advances functional proteomics with novel timsUltra AIP and timsOmni workflows for drug discovery & development and disease biology research.

Bruker advances functional proteomics with novel timsUltra AIP and timsOmni workflows for drug discovery & development and disease biology research. Sep 28 2026 12:00 BST * MultiDIA-PASEF significantly increases protein sequence coverage on timsUltra AIP * ProteoScape connects PASEF discovery with rapid prm-PASEF target validation * Spectronaut(R) AI transfer learning accelerates adaptation to new MS capabilities * Guided PASEF EXciD enables high-throughput glycopeptide characterization * Integrated HDX-MS workflows advance protein conformation and interaction studies * timsOmni(TM) enables RNA and DNA top-down structural and native RNA analysis SINGAPORE-(BUSINESS WIRE)-Sep. 28, 2026- At the Human Proteome Organization World Congress 2026, Bruker Corporation (Nasdaq: BRKR) today announced unique new timsUltra AIP and timsOmni workflows for deeper protein-sequence coverage, targeted validation, mobility-resolved glycopeptide characterization, structural proteomics, and oligonucleotide analysis. Multi-enzyme dia-PASEF provides additional peptide information for investigations of isoforms and proteoforms, while ProteoScape workflows connect PASEF discovery with prm-PASEF target validation on the same timsTOF platform. Novel timsOmni and integrated HDX-MS workflows extend structural analysis to glycopeptides, proteins, and nucleic acids.

MarketScreener
Sep 21st, 2026
Bruker Corporation receives order from University of California, Berkeley for high-field nmr systems for major upgrade of Magnetic Resonance research infrastructure.

Bruker Corporation receives order from University of California, Berkeley for high-field nmr systems for major upgrade of Magnetic Resonance research infrastructure. Published on 09/21/2026 at 09:36 am EDT S&P Capital IQ Bruker Corporation announced a multi-system order from University of California, Berkeley for high-field Nuclear Magnetic Resonance (NMR) instrumentation at the Pines Magnetic Resonance Center. The investment will enhance access to next-generation NMR technologies, including 800 MHz?class instrumentation. The investment is centered on a Bruker AV NEO-X 800 MHz spectrometer equipped with a cryogenically cooled MAS CryoProbe, complemented by several additional NMR systems and upgrades supporting solid-state, solution-state and Dynamic Nuclear Polarization (DNP) research. The UC Berkeley NMR order exceeds USD 6 million and is expected to be delivered in 2027. (C) S&P Capital IQ - 2026

U.S. Securities and Exchange Commission
Sep 19th, 2026
10-K

Market for Registrant’s Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities

U.S. Securities and Exchange Commission
Sep 18th, 2026
10-Q

Unaudited Condensed Consolidated Balance Sheets as of June 30, 2024 and December 31, 2023